Top Line: Does comprehensive bridging radiation improve outcomes for patients receiving CART for relapsed/refractory B-cell lymphoma?
The Study: Failure at pre-existing sites is a common pattern of progression following CART for B-cell lymphoma. For patients with a limited extent of disease, could bridging radiation to all sites increase the chances of success after CART? This retrospective study compared control and survival outcomes for 100 patients treated with CART who had <5 sites of disease. A third (34%) received bridging RT with a median EQD2 of 26.5 Gy. The rate of sustained complete response was significantly higher in patients who received bridging RT (62% v 36%), and the rate of local relapse was significantly lower (15% v 41%). There were also significant improvements in recurrence free (57% v 47%) and event free survival (45% v 37%) at 2 years, but this did not translate to a difference in 2-year OS (69% v 64%). There was no grade 3+ toxicity related to radiation.
TBL: For patients with relapsed B-cell lymphoma and a limited extent of disease prior to CART, bridging RT to all sites of disease was associated with better durable response and disease control. | Saifi, JAMA Oncol 2024
The Study: Failure at pre-existing sites is a common pattern of progression following CART for B-cell lymphoma. For patients with a limited extent of disease, could bridging radiation to all sites increase the chances of success after CART? This retrospective study compared control and survival outcomes for 100 patients treated with CART who had <5 sites of disease. A third (34%) received bridging RT with a median EQD2 of 26.5 Gy. The rate of sustained complete response was significantly higher in patients who received bridging RT (62% v 36%), and the rate of local relapse was significantly lower (15% v 41%). There were also significant improvements in recurrence free (57% v 47%) and event free survival (45% v 37%) at 2 years, but this did not translate to a difference in 2-year OS (69% v 64%). There was no grade 3+ toxicity related to radiation.
TBL: For patients with relapsed B-cell lymphoma and a limited extent of disease prior to CART, bridging RT to all sites of disease was associated with better durable response and disease control. | Saifi, JAMA Oncol 2024